Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 19/20 | 0.70 |
| ▸ | FLT1 | P17948 | 12/20 | 0.70 |
| ▸ | PDGFRB | P09619 | 11/20 | 0.70 |
| ▸ | KDR | P35968 | 11/20 | 0.70 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.70 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1050162 | 0.83 | FGFR1 (1.00) | FGFR1FLT1PDGFRBKDRCHEK1 | |
| SCHEMBL30737932 | 0.83 | FGFR1 (1.00) | FGFR1FLT1PDGFRBKDRCHEK1 | |
| SCHEMBL1055032 | 0.82 | FGFR1 (0.74) | FGFR1FLT1PDGFRBKDRCHEK1 | |
| SCHEMBL14795542 | 0.80 | FGFR1 (0.70) | FGFR1FLT1PDGFRBKDRCHEK1 | |
| SCHEMBL15910628 | 0.80 | FGFR1 (0.70) | FGFR1FLT1PDGFRBKDRCHEK1 | |
| SCHEMBL3383529 | 0.80 | FGFR1 (0.70) | FGFR1FLT1PDGFRBKDRCHEK1 | |
| SCHEMBL4291574 | 0.79 | FGFR1 (0.74) | FGFR1FLT1PDGFRBKDRCHEK1 | |
| SCHEMBL4296125 | 0.79 | FGFR1 (1.00) | FGFR1FLT1PDGFRBKDRCHEK1 | |
| SCHEMBL1054507 | 0.77 | FGFR1 (0.78) | FGFR1FLT1PDGFRBKDRCHEK1 | |
| SCHEMBL3732075 | 0.77 | FGFR1 (0.72) | FGFR1FLT1PDGFRBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2762475-A1 | Pharmaceutically acceptable salts of quinolinone compounds and their medical use | Novartis Vaccines and Diagnostics, Inc. (US) | 2014-08-06 | — | — | EP | disclosed |
| EP-2573079-A2 | Benzimidazole quinolinones and uses thereof | Novartis Vaccines and Diagnostics, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| CN-1960731-B | Method for regulating inflammatory and metastatic processes | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2011-12-07 | — | — | CN | disclosed |
| EP-1497287-B1 | Quinoline derivatives in combination with 5-FU or CPT-11 for use in the treatment of cancer | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2010-11-24 | — | — | EP | disclosed |
| US-7825132-B2 | Inhibition of FGFR3 and treatment of multiple myeloma | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20100184754-A1 | QUINOLINONE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | BARSANTI PAUL A | 2009-11-12 | — | — | US | disclosed |
| US-7598268-B2 | Quinolinone derivatives | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| CN-100526312-C | Benzimidazole quinolinones and uses thereof | CHIRON CORP (US) | 2009-08-12 | — | — | CN | disclosed |
| EP-1539754-A4 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-02-25 | — | — | EP | disclosed |
| CN-1483028-A | Quinolinone derivatives as tyrosine kinase inhibitors | ϣ | 2004-03-17 | — | — | CN | disclosed |
| WO-2004018419-A2 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | CHIRON CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
| US-20040006101-A1 | Quinolinone derivatives | CHIRON CORPORATION | 2004-01-08 | — | — | US | disclosed |
| US-20030158224-A1 | Quinolinone derivatives | CHIRON CORPORATION | 2003-08-21 | — | — | US | disclosed |
| US-6605617-B2 | Treating a patient in need of an inhibitor of vascular endothelial growth factor receptor tyrosine kinase | CHIRON CORPORATION | 2003-08-12 | — | — | US | disclosed |
| EP-1317442-A1 | QUINOLINONE DERIVATIVES AS TYROSINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-06-11 | — | — | EP | disclosed |
| US-20030028018-A1 | Quinolinone derivatives | CHIRON COPORATION | 2003-02-06 | — | — | US | disclosed |
| US-20020107392-A1 | Quinolinone derivatives | NOVARTIS AG (CH) | 2002-08-08 | — | — | US | disclosed |
| WO-2002022598-A1 | QUINOLINONE DERIVATIVES AS TYROSINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2002-03-21 | — | — | WO | disclosed |
| CN-1226283-A | Recombinant enzyme with dextranase activity | NOVO NORDISK AS (DK) | 1999-08-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | GAA, ALPI, IL4I1 | FGFR1 3018/4885FLT1 4604/4885PDGFRB 3508/4885 |
| US-20030028018-A1 | Quinolinone derivatives | SLCO1B1, SLCO1B3, SLCO1A2 | FGFR1 2797/4885FLT1 3748/4885PDGFRB 4039/4885 |
| US-20030158224-A1 | Quinolinone derivatives | SLCO1B1, SLCO1B3, SLCO1A2 | FGFR1 2797/4885FLT1 3748/4885PDGFRB 4039/4885 |
| US-20020107392-A1 | Quinolinone derivatives | SLCO1B1, SLCO1B3, SLCO1A2 | FGFR1 2797/4885FLT1 3748/4885PDGFRB 4039/4885 |
| US-20100184754-A1 | QUINOLINONE DERIVATIVES | SLCO1B1, SLCO1B3, SLCO1A2 | FGFR1 2959/4885FLT1 4072/4885PDGFRB 4032/4885 |
| US-20040006101-A1 | Quinolinone derivatives | SLCO1B1, SLCO1B3, SLCO1A2 | FGFR1 2797/4885FLT1 3748/4885PDGFRB 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.